FUJIFILM : 1st Quarter ended June 30, 2021 Earnings Presentation

Earnings of Q1 FY2021

August 13, 2021

Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are managementʼs current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties, and other factors. Accordingly, actual results may differ materially from those projected due to various factors.

Highlights of Performance for Q1 FY2021

Consolidated Performance for Q1 FY2021(Billions of yen)

		Actual	Change	Change
		from FY20 Q1	from FY19 Q1
Revenue			582.7	+27.7%	+8.8％
Operating Income			56.3	2.8 times	+51.7%
Net Income
Record	57.3	2.1 times	3.9 times
Attributable to
	high
FUJIFILM Holdings

• Revenue and profits increased in all business segments. Steady recovery from the previous fiscal year when performance was affected by COVID-19.
• Highest ever Q1 net income attributable to FUJIFILM holdings. In addition to favorable performance, major contribution was from valuation gains on marketable and investment securities resulting from the IPO of an advanced medical company in which we had invested.

■ Full-year Forecast for FY2021

(Billions of yen)

		Previous	Current	Change
		forecast	forecast
Revenue	2,440.0	2,500.0	+60.0
Operating Income	180.0	200.0	+20.0

Net Income

Attributable to130.0 160.0 +30.0

FUJIFILM Holdings

Full-year forecast has been revised upward reflecting strong Q1 performance.

1

Key Points of Performance for Q1 FY2021

Bio CDMO Business

Manufacturing capacity expansion plan*

•Decided to make large-scale capital

investment in the U.S. and Europe sites

Investment of approx. ¥90.0 billion;

operations planned to start in H2 2023

•Drug substance manufacturing capacity for

recombinant vaccines will be doubled in the

U.S. to meet the growing demand for

COVID-19 vaccines.

•In addition to expanded manufacturing

capacity, we will capitalize on industryʼs top-

class productivity to meet the growing

demand for biopharmaceuticals and

contribute to steady supply of high quality

*Manufacturing capacity at fiscal year-end

■Denmark site20㎘ x 6 units Operation to start in fall 2023

	337
	67
(Unit: ㎘)

180
39	270
141

■U.S. site20㎘ x 8 units Operation to start in spring

4972025

67

430

drugs.

FY21FY23FY25

Make aggressive capital investment to achieve FY2024 revenue target of ¥200.0 billion and CAGR of 20% in and after FY2025.

Key Points of Performance for Q1 FY2021

Life Sciences Business (Regenerative Medicine)

• Century Therapeutics, Inc., which U.S. subsidiary FCDI invested in and established with the aim of developing next-generation cancer immunotherapeutic drugs using allogeneic iPS cells, made IPO on the U.S. NASDAQ market. As a result, valuation gains on marketable and investment securities of ¥17.6 billion were recorded.
• A strategic R&D alliance agreement* was reached with BlueRock Therapeutics LP, a subsidiary of Germany- based Bayer AG, regarding iPS cell therapies for ocular diseases. An upfront payment of US$30 million has been received and up to US$40 million funding for R&D and part of investigational agent manufacturing is planned to be received for the development of the three retinal disease therapy programs.

iPS cell related

technology,

manufacturing

facilities, human

resources etc.

Strengthen alliance with partner companies

・Joint R&D

・Supply therapeutic iPS cells

・iPS cell-related patent licensing

・Contract process development / manufacturing of regenerative medicine products (CDMO)

・Development / sales milestone and royalty payments

Pharmaceutic al companies Bio ventures

Strengthen alliance with partner companies and promote industrialization of cell therapy in the regenerative medicine field by leveraging our iPS cell technology and manufacturing facilities

*Tri-party agreement between FUJIFILM Cellular Dynamics, Inc. (FCDI), Opsis Therapeutics, LLC, (both Fujifilm group companies) and BlueRock Therapeutics LP, which is a subsidiary of major pharmaceutical company Bayer AG

2

Consolidated Performance for Q1 FY2021

(April 2021- June 2021)

(Billions of yen)

							Q1
		FY2020		FY2021	Change	Impact of	Constant-
			exchange rate	currency basis
Revenue		456.3			582.7	126.4	19.7	106.7
	100.0%			100.0%	+27.7%		+23.4%
Operating Income	20.4			56.3	35.9	4.0	31.9
4.5%			9.7%	2.8 times		2.6 times
Income before	42.2				77.8	35.6	5.1	30.5
highRecord
Income Taxes	9.2%				13.3%	+84.3%		+72.3%
Net Income Attributable to	27.5		highRecord		57.3	29.8	3.5	26.3
FUJIFILM Holdings	6.0%			9.8%	2.1 times		+95.6%
Net Income Attributable to	¥68.80		¥143.34	¥74.54	Other change factors (YoY):
FUJIFILM Holdings per Share							Impact of raw materials prices on
					¥1	operating income: -¥5.3 billion
Exchange US$/￥	¥108			¥109
Rates	€/¥	¥119			¥132	¥13

Consolidated Revenue and Operating Income by Operating Segment

(Billions of yen)

Revenue		Q1	Change	Constant-currency
	FY2020	FY2021	basis
Healthcare		110.2	174.2	64.0	(+58.0%)	58.8	(+53.3%)
Materials		127.4	149.8	22.4	(+17.7%)	17.9	(+14.2%)
Business Innovation		168.9	186.1	17.2	(+10.2%)	11.0	(+6.5%)
Imaging		49.8	72.6	22.8	(+45.6%)	19.0	(+38.0%)
Total		456.3	582.7	126.4	(+27.7%)	106.7	(+23.4%)
Note: After elimination of	intersegment transactions
						(Billions of yen)
		Q1			Constant-currency
Operating Income			Change
FY2020	FY2021	basis
Healthcare		4.4	20.7	16.3	(4.7 times)	15.5	(4.6 times)
Materials		13.1	21.3	8.2	(+62.9%)	7.6	(+58.4%)
Business Innovation		13.4	14.0	0.6	(+4.5%)	(0.2)	(-1.3%)
Imaging		(3.0)	8.0	11.0	Turned to	9.1	Turned to
	the black	the black
Corporate Expenses &	(7.5)	(7.7)	(0.2)	-	(0.1)	-
Eliminations
Total		20.4	56.3	35.9	(2.8 times)	31.9	(2.6 times)

3

Summary by Operating Segment: Healthcare

• In addition to organic growth in all sub-segments, consolidation of FUJIFILM Healthcare in the medical systems business contributed to a sharp year-over-year increase of 58% in revenue and a 4.7 times increase in operating income.

(Billions of yen)	174.2				Medical systems: Revenue ¥114.2 billion (up 67.1% YoY)
180.0						40.0	• In addition to turning FUJIFILM Healthcare into a consolidated
160.0								subsidiary, the steady demand for ultraportable digital X-ray
						35.0	imaging systems and ultrasound diagnostic devices, both useful
140.0							30.0	for pneumonia diagnosis, contributed to a surge in revenue.
						Bio CDMO: Revenue ¥33.9 billion (up 72.5% YoY)
120.0	110.2		114.2
			25.0	• Favorable performance of contract process development and
100.0							20.0	manufacturing of biopharmaceuticals and manufacture of drug
							substances for COVID-19 vaccine candidates at the U.S. site
80.0	68.4					15.0	resulted in a surge in revenue.
60.0							Life sciences*: Revenue ¥26.1 billion (up 17.5% YoY)
				20.7		10.0
40.0	19.6		33.9		• In the life sciences business, solid sales of cell culture media for
		(11.9%)
20.0	4.4	5.0	biopharmaceutical manufacturing led to a surge in revenue.
	22.2	(3.9%)	26.1				• In the consumer healthcare business, favorable sales of
0.0							0.0	Metabarrier EX and other supplements and steady sales of new
	Q1 FY20	Q1 FY21		cosmetic products contributed to higher revenue.
Medical systems Bio CDMO	Life sciences	*Life sciences: Disclosure segment consisting of life sciences business
(cells, culture media, reagents), pharmaceutical business, and

Operating income (margin)	consumer healthcare business (cosmetics, supplements)

Summary by Operating Segment: Materials

• Significant year-over-year increases of 17.7% in revenue and 62.9% in operating income led by steady recovery from the COVID-19 pandemic as well as growth in the electronic materials business in tandem with the increasing demand for semiconductors.

(Billions of yen)						Electronic materials: Revenue ¥33.7 billion (up 16.1% YoY)
								•	Revenue rose on favorable sales of wide ranging products,
160.0				149.8			40.0		including CMP slurries and polyimide, reflecting a rise in
						semiconductor demand.
140.0	127.4		33.7			35.0	Display materials: Revenue ¥24.8 billion (up 19.6% YoY)
120.0						30.0	•	Revenue rose on strong sales of various high-functioning film,
29.0
					driven by the steady demand for smartphones as well as a rise
100.0				24.8			25.0		in demand for monitors, tablets and TVs amid the COVID-19
	20.7							pandemic.
80.0		23.8			20.0	Other high-functioning materials*: Revenue ¥23.8 billion
60.0	20.7					15.0	(up15.6% YoY)
						•	In the recording media business, revenue increased due to a
40.0				67.5	21.3		10.0		gradual recovery in demand for tapes, which had fallen amid
	57.0	13.1	(14.2%)		the COVID-19 pandemic.
20.0				5.0	Graphic communication: Revenue ¥67.5 billion (up 18.5% YoY)
			(10.3%)				•	Revenue rose as active implementation of online negotiations
0.0							0.0
							led to higher sales.
Q1 FY20	Q1 FY21
				•	In the inkjet business, revenue increased on steady sales of
									industrial inkjet printheads, reflecting the growing demand in
Electronic materials	Display materials Other high-functioning materials	the ceramics markets in China and Europe.
Graphic communication	Operating income (margin)		*Other high-functioning materials: Disclosure segment consisting of
								industrial products business, fine chemicals business, and recording

media business.

4

Summary by Operating Segment: Business

Innovation

• Revenue and operating income increased 10.2% and 4.5% year-over- year respectively as the business recovered from the COVID-19 pandemic.
• Started to launch new products under the FUJIFILM brand. We will further accelerate global expansion including new OEM supplies.

(Billions of yen)						Office solutions: Revenue ¥127.6 billion (up 9.5% YoY)
200.0					186.1	40.0
				•	In the office products field, unit sales increased year-over-year
180.0	168.9			35.0		in Japan, China, and the Asia-Pacific region,and also for exports
							to Europe and the U.S. After-sales revenue also rose sharply,
160.0
					30.0		driven by the recovery from the COVID-19 pandemic.
140.0						•	For global expansion under the FUJIFILM brand, new models of
120.0					127.6	25.0		Apeos series, digital color multifunction devices / printers with a
116.4		20.0		totally new design and stronger security features, were
100.0							released in April 2021.
80.0						15.0	Business solutions: Revenue ¥58.5 billion (up 11.5% YoY)
60.0						10.0
40.0						•	Revenue climbed due to acquisition of system orders from
			13.4	58.5 14.0(7.5%)5.0		domestic municipalities and a sales increase in the BPO
20.0	52.5
			(7.9%)				(Business Process Outsourcing) business mainly overseas.
0.0							0.0	•	Of total revenue, the "industrial solution field" centering on the
	Q1 FY20	Q1 FY21				BPO business that offers document digitalization accounts for
									60%, and "DX solution field" centering on IT outsourcing that
									provides IT infrastructure for the SMB market accounts for
Office solutions	Business	(OperOperating Margin)	40%. Aim to accelerate growth by strengthening both fields
					solutions	income		further.

(margin)

Summary by Operating Segment: Imaging

• Performance recovered sharply as revenue surged 45.6% YoY and operating income returned to the black year-over-year, due to strong sales of instant photo systems.

72.6

49.8

44.9

27.8

22.027.7 8.0

(11.0%)

Q1 FY20	-3.0	Q1 FY21
	(-6.0%)

Operating income (margin)

Consumer imaging: Revenue ¥44.9 billion (up 61.0% YoY)

• In addition to the recovery from the COVID-19 pandemic, revenues soared year-over-year on solid sales of instant photo systems and dry minilabs / materials for retailers in the U.S.
• As an entry model of instant photo systems, the instax mini 40 compatible with mini format film was released in April 2021. It was rated highly in the market for its classic camera design that never goes out of style, and achieved firm sales in Japan and overseas.

Professional imaging: Revenue ¥27.7 billion (up 26.1% YoY)

• FUJIFILM GFX100S, a mirrorless digital camera which has gained a high reputation worldwide for its superior image quality using a large format sensor despite its compact body, increased its user base and continued to boost sales.
• Revenue climbed as sales of broadcast and cinema lenses, which had been hit by a drop in demand due to the COVID-19 pandemic, began to pick up. Sales in the monitoring / measurement field, including long-range surveillance cameras and machine vision lenses, also fared well.

5